



## Fosrenol® (lanthanum carbonate) – First-time generic

- On August 14, 2017, [Natco Pharma announced](#) the approval of its [AB-rated](#) generic to Shire's [Fosrenol \(lanthanum carbonate\)](#) chewable tablets, to reduce serum phosphate in patients with end stage renal disease.
  - In addition, [Prasco Laboratories](#) signed an exclusive distribution and supply agreement with Shire for an authorized generic version of Fosrenol chewable tablets. As part of the agreement, Prasco will market its generic under the Prasco label in response to the first generic entrant.
- Brand Fosrenol is also available as an oral powder in 750 mg and 1,000 mg strengths.
- Annual U.S. sales for Fosrenol chewable tablets were \$122.4 million as of June 2017.
- Natco Pharma and its partner, Lupin, plan to launch generic Fosrenol chewable tablets shortly.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.